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Abstract
We present a dynamical model of lipoprotein metabolism derived by combining a
cascading process in the blood stream and cellular level regulatory dynamics. We
analyse the existence and stability of equilibria and show that this low-dimensional,
nonlinear model exhibits bistability between a low and a high cholesterol state. A
sensitivity analysis indicates that the intracellular concentration of cholesterol is
robust to parametric variations while the plasma cholesterol can vary widely. We
show how the dynamical response to time-dependent inputs can be used to diagnose
the state of the system. We also establish the connection between parameters in the
system and medical and genetic conditions.
Key words: lipoprotein metabolism, dynamical systems, nonlinear models,
metabolic control mechanisms, statins, familial hypercholesterolemia
1 Introduction
We model the dynamics of lipoprotein metabolism associated with the trans-
port of lipids in the blood. The malfunction of the delivery of lipids and
cholesterol from the liver to the cells has important ramifications. There is
strong medical evidence linking high plasma concentrations of low-density
lipoproteins (LDL) to the development of atherosclerosis, the deadliest disease
in industrialised countries (Glass and Witztum, 2001; Rodr´iguez et al., 1999;
Libby, May 2002). However, LDL is just one species in a metabolic cascade by
which different lipoproteins (Table 1) are synthesised, degraded and absorbed.
In this complex network, it is important to investigate how metabolic control
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is exercised and if dynamical features, other than high LDL concentrations,
could be useful markers for the detection of disease states.
Previous modelling efforts of lipoprotein metabolism vary in scope. Some mod-
els have concentrated on detailed aspects of the system, such as the fluid dy-
namics of lipid accumulation on the arterial walls (Hazel and Pedley, 1998)
or the chemical kinetics of LDL oxidation (Cobbold et al., 2002), but do not
describe the processes at the cellular or physiological level. Other approaches
have modelled the lipoprotein network as a whole with linear compartmen-
tal models (Jacquez, 1985; Pont et al., 1998; Parhofer et al., 1991). Although
these models can be fitted to match experimental data, the compartments lack
rigorous physiological meaning, thus making it difficult to describe the under-
lying biochemical processes. For instance, compartments added to represent
subclasses of lipoproteins can always be reduced to one compartment because
of the linearity of the models (Eisenfled and Grundy, 1984).
Our model of lipoprotein metabolism is a relatively low-dimensional system
of nonlinear differential equations which are strongly linked to the underlying
physiological processes. The system can undergo a transition between low
and high LDL steady states, a feature which is robust to randomness and
uncertainty in the parameters. Because the equations are directly related to
physiological processes, the model can be used to study the effect of genetic
or behavioral conditions and could serve as an aid to test hypotheses for
diagnosis and intervention. In what follows, we derive our model from the main
physiological processes; we then analyse the system and carry out a sensitivity
analysis; finally, we show how the results can be related to experiments and
medical conditions.
2 Modelling Lipoprotein Metabolism
Lipoproteins constitute the primary means of transport of lipids from the liver
to the cells via the blood stream. Lipoprotein dynamics is intimately connected
to lipid and cholesterol metabolic networks. Figure 1 provides a schematic
overview of the origin, transport and fate of the different lipoproteins in the
human body at two levels: the macroscopic and the cellular.
Lipoproteins are globular aggregates of lipids and proteins: cholesterol ester
and triacylglycerol form the core; amphiphilic phospholipids surround them
forming the hull; and different apolipoproteins (apo A, apo B, apo C, and apo
E), which function as trigger-molecules for specific reactions, are embedded
in the surface. Lipoproteins are classified in five standard groups (Table 1),
based on density and the apolipoproteins attached to them. In increasing or-
der of density and decreasing order of size (the fewer lipids relative to its size,
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the denser the lipoprotein is): chylomicrons (Chyl), very low-density lipopro-
teins (VLDL), intermediate-density lipoproteins (IDL), low-density lipopro-
teins (LDL), and high-density lipoprotein (HDL).
Chyl VLDL IDL LDL HDL
Density (g/ml) < 0.95 0.95–1.006 1.006–1.019 1.019–1.063 1.063–1.21
Diameter (nm) 80–100 30–80 25–30 20–25 8–13
Cholesterol (%) 3–5 12–21 27–46 40–50 15–25
Apolipoproteins A, C, E, B-48 C, E, B-100 C, E, B-100 B-100 A, C, E
Table 1
The properties and composition of the five standard lipoprotein
classes (Adiels, 2002): chylomicrons (Chyl), very low-density lipoproteins (VLDL),
intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and high-
density lipoproteins (HDL).
Chylomicrons contain a large proportion of fatty acids and are found in the
blood stream mainly after digestion of a meal. They are synthesised by the
intestines and constitute the direct means by which dietary fat is delivered to
heart, muscle, and adipose tissue. Chylomicrons provide the liver with lipids
and proteins but are not regulated by the liver. Therefore, we do not consider
the concentration of chylomicrons as an explicit variable in our model and
include their effect parametrically as an input of lipids to the system.
The liver is responsible for the secretion of all other lipoproteins, most sig-
nificantly VLDL. (Although small amounts of IDL and LDL are produced by
the liver, we neglect this contribution.) VLDL is secreted by the liver into
the blood at an almost constant rate (slightly higher during the night) as a
means of transport of synthesised fat and cholesterol to peripheral tissues.
While in the blood stream, the apo C protein on the surface of VLDL can
bind to the extracellular enzyme lipoprotein lipase (LPL), which is present
on the capillary wall. The effect of LPL is to hydrolyse triacylglycerol, thus
reducing the size of VLDL and increasing the percentage of denser molecules
(i.e., it degrades VLDL to IDL). After hydrolysis, the fatty acids are taken up
by nearby cells or by serum albumin for transport to more peripheral cells. A
similar process leads from IDL to LDL. This is the lipoprotein cascade that
transforms VLDL into IDL into LDL. (This process also involves losing apo
C and apo A to HDL, which is independently synthesised in the liver and is
not a part of the lipoprotein cascade.)
About 50% of the IDL and 75% of LDL in the blood are absorbed by hepatic
and peripheral cells via LDL receptors (LR) on the cell membrane. These re-
ceptors are synthesised by the cell and recognise apo B and apo E with high
affinity. In liver cells, the absorbed LDL is reused for lipoprotein synthesis and
excess cholesterol is secreted into bile. In non-hepatic cells, the absorbed LDL
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Fig. 1. Overview of origin, transport and fate of lipoproteins. A schematic
view of the processes involved in the metabolism of lipoproteins at both the macro-
scopic and cellular levels. The liver secretes VLDL at a rate uV . The turnover rates
of VLDL and IDL in the blood stream are kV and kI , respectively. At the cellular
level, dL and dI denote rate constants of the receptor-mediated uptake of lipopro-
teins: IDL and LDL bind to membrane receptors (LR), which cluster in coated pits
in the cell membrane. Note that it is also possible for LDL (but not for IDL) to be
absorbed directly through a non-receptor mediated path with rate constant d. After
endocytic vesicles are formed and internalised, the lipoproteins are hydrolysed in the
cell releasing lipids into the cytoplasm. A significant proportion of these lipids (χI
in IDL and χL in LDL) is cholesterol which contributes to the level of intracellular
cholesterol (IC). The intracellular cholesterol is used for cell function or eliminated,
mainly through the action of HDL, at a rate dIC . Most of the LDL receptors (but
not all) are reincorporated into the membrane. In addition, the nuclear synthesis
of the receptors LR is regulated through negative feedback (⊢) by the intracellular
cholesterol IC.
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supplies the cholesterol content essential for cell function (White and Baxter,
1984; Chopra and Thurnham, 1999). Although almost every cell can synthe-
sise cholesterol to some extent, we assume that all cholesterol has to be deliv-
ered to the cells via LDL or IDL absorption (Mathews et al., 2000; Cooper,
2000; Converse and Skinner, 1992; Dietschy et al., 1978).
As mentioned above, there is another important component in the lipoprotein
network: HDL (the “good cholesterol”), which is also secreted by the liver.
HDL is responsible for reverse cholesterol transport, the transport of excess
cholesterol from cells and other lipoproteins back to the liver. The effect of
HDL is included in our model through a rate constant that parameterises the
elimination of intracellular cholesterol, which is significantly affected by the
HDL pathway.
The above processes can be modelled with the following system of differen-
tial equations, where [·] denotes concentration and φLR is the dimensionless
fraction of total possible LDL receptors:
d[V LDL]
dt
= −kV [V LDL] + uV (1)
d[IDL]
dt
= kV [V LDL]− kI [IDL]− dI [IDL]φLR (2)
d[LDL]
dt
= kI [IDL]− dL[LDL]φLR − d[LDL] (3)
dφLR
dt
= −b (dI [IDL] + dL[LDL])φLR + c
1− φLR
[IC]
(4)
d[IC]
dt
= (χIdI [IDL] + χLdL[LDL])φLR + χLd[LDL]− dIC[IC]. (5)
The linear terms kV [V LDL] and kI [IDL] in (1)–(3) correspond to the cascade
degradation of VLDL to IDL to LDL assuming saturated kinetics (i.e., excess
of LPL enzyme) for the reactions. An implicit assumption is that the blood
flow does not play a significant role in the absorption process. This is based
on our analysis of the relevant time scales and also on detailed calculations of
mass transfer in tissue under physiological conditions (Zhang, 2005).
Equation (1) contains the only input to the system, uV , which represents the
overall secretion rate of VLDL by the liver. High values of uV are associated
with a high dietary intake of fats (Spady et al., 1993). On the other hand,
medication with statins would reduce uV by lowering the synthesis of choles-
terol and VLDL in the liver.
The nonlinear terms dI [IDL]φLR and dL[LDL]φLR represent the endocytosis
of IDL and LDL via a process involving LDL receptors (LR) and leading to
the release of lipids and cholesterol into the cytoplasm. This can be modelled
in its simplest, classical form through a second order reaction (Bywater et al.,
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2002). In addition to this receptor-mediated uptake, mammalian cells can take
up LDL (but not IDL) by non-specific endocytosis at a rate d[LDL], linearly
proportional to its plasma (or extracellular) concentration (Hobbs et al., 1990;
Willnow et al., 1999; Glass and Witztum, 2001; Goldstein and Brown, 1997).
Endocytosis is greatly reduced under the genetic disease familial hypercholes-
terolemia (Section 4.1.3).
The last two equations (4)–(5) describe cholesterol uptake and regulation at
the cellular level. The variables are: φLR, the fraction of the total possible LDL
receptors that mediate IDL and LDL endocytoses; and [IC], the concentration
of cellular cholesterol, which closes the loop by acting as a cellular control for
the expression and synthesis of the LDL receptors, LR.
Parameter Source Units Nominal Value Range
kV (Packard et al., 2000) h
−1 0.3 0.15–0.6
kI (Packard et al., 2000) h
−1 0.1 0.025–0.1
dI — h
−1 1.4 0.5–2
dL — h
−1 0.005 0.005–0.02
d (Dietschy et al., 1993) h−1 0.0025 0.0025-0.0075
b — lg−1 0.1 0–2
c (Goldstein and Brown, 1977) g(lh)−1 0.05 0–1
χI (Adiels, 2002) – 0.35 0.25–0.45
χL (Adiels, 2002) – 0.45 0.4–0.5
uV (White and Baxter, 1984) g(lh)
−1 0.3 Variable
dIC (White and Baxter, 1984) h
−1 0.45 Variable
Table 2
Parameters of the model (1)-(5). Nominal values and ranges as found in the
literature. The nominal values for dI and dL are obtained by assuming that all other
parameters are at nominal values and the equilibrium point of the linearised system
in the lower branch of Eq. (17) is that of normal individuals (White and Baxter,
1984): [V LDL] = 1 gl−1, [IDL] = 0.2 gl−1, [LDL] = 2 gl−1. The nominal values
for uV and dIC are crude estimates from the cited reference. Because of their high
dependence on diet, medication and genetic factors, we consider uV and dIC as the
control parameters.
Eq. (4) reflects the dynamical processes involving the LDL surface receptors,
which take part in the endocytotic reactions. Experiments in normal individ-
uals indicate that the maximum number of receptors on the surface of the cell
is 15, 000 − 70, 000 per cell (Goldstein and Brown, 1977). The variable φLR
represents the fraction of the total possible surface receptors that are present
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on the surface of the cell. Therefore, φLR is a surface occupancy fraction; hence
it is dimensionless and bounded (0 ≤ φLR ≤ 1). Biological evidence indicates
that most (but not all) of the receptors used in the endocytosis are reinte-
grated into the cell membrane. The first term in (4), weighted by a factor
b, represents the loss of LDL receptors that are not recycled. The last term
in (4) describes the cholesterol-regulated synthesis of LDL receptors and the
process of their attachment to the surface of the cell. Further biological evi-
dence indicates that cells regulate the synthesis of LDL receptors to prevent
the over-accumulation of intracellular cholesterol. When grown in the presence
of different concentrations of LDL, cells adjust the number of LDL receptors to
take up only enough LDL to satisfy the cholesterol requirement for membrane
turnover (Goldstein and Brown, 1977); when grown in total absence of LDL,
the maximum number of possible surface LDL receptors is reached after 2–3
days. We have modelled this inhibitory mechanism with a simple reciprocal
feedback: the synthesis of cytosolic LDL receptors is inversely proportional
to the intracellular cholesterol [IC]. Furthermore, the attachment of the cy-
tosolic LDL receptors to the cell surface can be described in its simplest form
with a rate that is proportional to the fraction of unoccupied receptor sites
(1 − φLR). The combined rate at which φLR increases is then given by the
product c(1− φLR)/[IC], where c modulates the weight of the combined pro-
cess of regulated synthesis and attachment. However, we emphasise that the
qualitative results of the model do not depend on the particular form of the
feedback chosen, as we discuss at the end of Section 3.2. For a more detailed
explanation of this term see Appendix A.
Finally, Eq. (5) establishes the balance of flows of the cellular cholesterol [IC].
The parameters 0 < χI < χL < 1 are the proportions of cholesterol in IDL and
LDL, respectively, which can be measured experimentally. The last term in the
equation dIC [IC] represents the outflow rate of cholesterol from the cell. This
is largely related to the HDL-mediated reverse cholesterol transport, but also
accounts for the cholesterol used by cells for their metabolism or eliminated
through bile secretion in the liver. Therefore, our model parameterises the
effect of HDL through the constant dIC . As in the case of uV , dIC will be a
highly variable control parameter which can be affected by diet and statins.
The model has eleven parameters with nominal values and ranges shown in
Table 2:
Model parameters: kV , kI , dI , dL, d, b, c, χI , and χL. These will differ
between individuals but are assumed to remain virtually unchanged for an
individual except for slow changes (e.g., with age). We have found values
and estimates in the literature for all of these parameters, except for b for
which we assume b = 0.1. Sensitivity analyses will be performed to check
that the qualitative results are robust to variations in these parameters.
Control parameters: uV and dIC . The secretion rate of VLDL from the
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liver (uV ) and the depletion rate of intracellular cholesterol (dIC) are highly
variable parameters and affected by genetic factors, diet and medication.
Hence, we will consider these as the control parameters for our analysis.
3 Model Analysis: Fixed Points and Sensitivity Analysis
3.1 The System at Equilibrium
We have carried out a numerical analysis of the bifurcations and fixed points
of the dynamical system (1)–(5). Before presenting the numerics, we briefly
note some analytical features of the model.
The system is effectively four-dimensional since [V LDL] converges exponen-
tially to its equilibrium value [V LDL]eq = uV /kV . Moreover, we can restrict
our analysis to the non-negative orthant because the system is essentially
non-negative, i.e., solutions remain non-negative for non-negative initial con-
ditions (Haddad et al., 2001). The equilibrium point can also be bounded from
above using the nullclines of (1)–(5) to give:
uV
kI + dI
≤ [IDL]eq ≤
uV
kI
(6)
kI uV
(kI + dI)(d+ dL)
≤ [LDL]eq ≤
uV
d
(7)
0 ≤ φLReq ≤ 1 (8)
χIdI + χLkI
kI + dI
uV
dIC
≤ [IC]eq ≤
χLuV
dIC
. (9)
The equilibrium approaches the bounds (6)–(9) asymptotically as uV → 0 and
uV →∞, as shown in Figure 2. The simple linear bounds (6)–(9) represent well
the asymptotic behaviour although tighter nonlinear bounds (not shown) can
be obtained. In conclusion, there is a compact, connected, positively invariant
bounding region for the system. This implies that any linearly stable solution
in this region is also locally asymptotically stable.
Consider now the fixed points of system (1)–(5) which are the solutions to the
following algebraic equation:
φ4LReqdICcd
2
IdL + φ
3
LReq
(
dICcdI(2kIdL + dI(d− dL)) + u
2
V bd
2
IdLχI
)
+ φ2LReq
(
dICc(2kIdI(d− dL) + k
2
IdL − d
2
Id) + u
2
V bdI(dLkI(χI + χL) + ddIχI)
)
+ φLReq
(
dICckI(kI(d− dL)− 2dId) + u
2
V bkI(ddIχL + dLkIχL)
)
− dICck
2
Id = 0
(10)
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together with{
[V LDL]eq =
uV
kV
; [IDL]eq =
uV
kI + dIφLReq
; [LDL]eq =
kI [IDL]eq
d+ dLφLReq
;
[IC]eq =
(χIdI [IDL]eq + χLdL[LDL]eq)φLReq + χLd[LDL]eq
dIC
}
.
(11)
Descartes’ rule of signs implies that the number of positive equilibria is 1
or 3. If we assume that the system has neither (quasi)periodic solutions nor
strange attractors (which never appear in our numerics), then if there is only
one fixed point, it is globally asymptotically stable; and if there are three, two
are locally asymptotically stable and one is unstable and lies “between” the
two stable points.
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Fig. 2. Plot of equilibrium solutions versus uV . We show stable solutions
(solid lines), unstable solutions (dotted lines), and bounds (6)–(9) (dashed lines)
as a function of uV with parameters: { kV = 0.3h
−1, kI = 0.025h
−1, dI = 2h
−1,
dL = 0.01h
−1, d = 0.0075h−1, χI = 0.1, χL = 0.6, b = 0.1lg
−1, c = 0.05g(lh)−1;
dIC = 1h
−1 }. For this set of parameters the system shows bistability. The bifur-
cations, obtained through (14), occur at: uV,bif ≈ 1.637 and uV,bif ≈ 1.811. The
approximation (16) to the latter is 1.759.
We numerically explore the fixed point equation (10) and record how the num-
ber and stability of positive fixed points change as the control parameters are
varied. Figure 2 shows a numerical bifurcation diagram as a function of uV ,
for a given set of parameters. The system has two distinct (sometimes coex-
isting) stable solutions: a low and a high cholesterol branch. For small (high)
uV , only the low (high) branch exists. For intermediate values of uV , the two
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stable branches (high and low) and an unstable solution coexist. The existence
of this coexistence region leads to the possibility of hysteresis and a delayed
return to the normal state when uV is swept. The transitions that delimit
the coexistence region are two saddle-node bifurcations. A similar bifurcation
diagram (Figure 3), with equivalent saddle-node bifurcations, is obtained by
sweeping the other control parameter dIC, although in this case the transition
to a higher cholesterol state is produced by decreasing dIC . These bifurcations
could be of physiological relevance because the parameters uV and dIC can be
regulated through diet and medication.
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Fig. 3. Equilibrium solutions versus dIC .We show stable solutions (solid lines),
unstable solutions (dotted lines), and bounds (dashed lines) as a function of dIC .
All parameters as in Fig. 2 and uV = 1 g(lh)
−1. The bifurcations for this set of
parameters, obtained through (14), occur at: dIC,bif ≈ 0.373 and dIC,bif ≈ 0.305.
The approximation (16) to the latter is 0.323.
The nature of the bifurcation diagram depends on the non-control parame-
ters of the model. In fact, the coexistence region does not exist in certain
regions of parameter space. In that case, the transition from the low to the
high cholesterol solution is smooth, without undergoing a bifurcation (i.e., no
sudden jumps and no hysteresis). We make this more precise by analysing the
equation for the bifurcation points. Rewrite the fixed point equation (10) as:
(y − 1)(y + g)(y + f)2 + Z y (y + hf)(y + f + g) = 0 (12)
where y = φLReq and the following ratios of parameters have been defined:
e = b/c, f = kI/dI , g = d/dL, h = χL/χI , Z = u
2
V e χI/dIC. (13)
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The bifurcation points are the solutions of an augmented system of equations,
formed by the fixed point equation and the condition that the Jacobian of (1)–
(5) vanishes. Using Groebner bases (or considerations about monotonicity and
curvature of (12)) we obtain a quintic polynomial equation for the bifurcation
points ybif:
y5bif + (2 g + 2 f h+ f) y
4
bif + (g
2 + 3 f 2 h+ f − f h− g f + 4 f h g) y3bif
+ (4 g f + f 2 − f 2 g + f 3 h− 2 f h g + 2 f 2 h g − g2 f − f 2 h+ 2 f h g2) y2bif
+ (2 f 2 g − f h g2 + 2 g2 f + f 2 h g) ybif + f
3 h g + f 2 h g2 = 0. (14)
Based on Descartes’ rule, we conclude that there is no coexistence region (and
no bifurcations) if:
g2 + 3 f 2 h + f − f h− g f + 4 f h g > 0
4 g f + f 2 − f 2 g + f 3 h− 2 f h g + 2 f 2 h g − g2 f − f 2 h + 2 f h g2 > 0
2 f 2 g − f h g2 + 2 g2 f + f 2 h g > 0.
These inequalities can be tested for each set of parameters to establish a
sufficient condition for the saddle-node bifurcations to exist.
Further insight can be gathered through explicit approximate formulas for the
bifurcations. Consider the limit case with d = 0, i.e., when there is no direct
uptake of cholesterol by the cell and only receptor-mediated intake is possible.
In this case, the fixed point equation (12) simplifies to:
y (y + f)
(
y2 + (f − 1 + Z)y + f(Zh− 1)
)
= 0,
leading to the following bifurcation points for this limit case:
4f(Zh− 1) = 0 ⇒ u∗V,bif =
√
dIC
eχI h
(15)
(f − 1 + Z)2
f(Zh− 1)
= 4 ⇒ u∗V,bif =
√
dIC
eχI
(
1− f + 2fh− 2
√
f(h− 1)(fh+ 1)
)
. (16)
Eq. (16) marks the point above which the low cholesterol branch ceases to
exist and serves as a good approximation for the bifurcation of the full model if
d is small. The approximate formulas (15)–(16) explain the overall dependence
on uV and dIC of the bifurcation points shown in Figs. 2 and 3.
3.2 Sensitivity Analysis of the Equilibrium Solution
In order to ascertain how variations in parameter values (e.g., among individ-
uals or due to age) affect the results, we perform a sensitivity analysis of the
11
Parameter Variable
Sensitivity over lower branch (uV ≤ uV,max)
Median Range
kI ∈ [0.025, 0.1] [IDL] 0.027 [0.0038, 0.036]
(uV,max = 1.1) [LDL] 1.18 [1.16, 1.26]
φLR 0.013 [3.1 × 10
−4, 0.074]
[IC] 0.17 [0.15, 0.21]
dI ∈ [0.5, 2] [IDL] 1.83 [1.79, 2.23]
(uV,max = 1.4) [LDL] 1.85 [1.79, 2.48]
φLR 0.023 [3.1 × 10
−4, 0.22]
[IC] 0.18 [0.16, 0.34]
dL ∈ [0.005, 0.02] [IDL] 5.3× 10
−4 [8.5× 10−6, 0.0038]
(uV,max = 1.3) [LDL] 0.82 [0.67, 0.87]
φLR 5.4× 10
−4 [8.6× 10−6, 0.0039]
[IC] 3.4× 10−5 [5.0× 10−7, 3.4 × 10−4]
d ∈ [0.0025, 0.0075] [IDL] 4.6× 10−4 [5.9× 10−6, 0.0045]
(uV,max = 1.4) [LDL] 0.38 [0.34, 0.50]
φLR 4.7× 10
−4 [6.0× 10−6, 0.0046]
[IC] 3.0× 10−5 [3.5× 10−7, 4.3 × 10−4]
e = b/c ∈ [0.25, 2.5] [IDL] 0.15 [0.0024, 0.80]
(uV,max = 1.4) [LDL] 0.23 [0.0037, 1.23]
φLR 0.15 [0.0024, 0.70]
[IC] 0.0093 [1.4 × 10−4, 0.064]
χI ∈ [0.25, 0.45] [IDL] 0.12 [0.0039, 0.76]
(uV,max = 0.9) [LDL] 0.18 [0.0062, 1.06]
φLR 0.12 [0.004, 0.71]
[IC] 0.56 [0.56, 0.56]
χL ∈ [0.4, 0.5] [IDL] 0.0018 [2.4 × 10
−5, 0.014]
(uV,max = 1.4) [LDL] 0.0027 [3.8 × 10
−5, 0.21]
φLR 0.0018 [2.5 × 10
−5, 0.015]
[IC] 0.013 [0.012, 0.021]
Table 3
Sensitivity of the variables of the model on the lower branch to variation
of parameters one at a time. The sensitivity is calculated as the range divided
by the median of each variable for five different values of the parameter that appears
in the first column. The third and fourth columns report the median sensitivity and
the range of calculated sensitivities over the lower branch (up to the value uV,max).
The salient feature of the analysis is the high sensitivity of [LDL] to all parameters
and the relative insensitivity of [IC] to almost all parameters.
12
system. Because of its physiological relevance, we focus on the variability of
the low cholesterol branch under parameter uncertainty.
Table 3 summarises the sensitivity of the low cholesterol branch when pa-
rameters are modified one at a time. Consider for instance the effect of d,
which parameterises the non-specific uptake of LDL. We have calculated nu-
merical bifurcation diagrams similar to those in Figure 2 for values of d ∈
[0.0025, 0.0075]. As d is varied, the values of the lower and upper branches
and the location of the bifurcations change. However, as expected from (6)–(9),
only the [LDL] is affected significantly. To make this more precise, we calcu-
late the sensitivity for each variable over the lower branch (uV ≤ 1.4 g(lh)
−1)
by obtaining the average ratio of the range and median of the equilibrium val-
ues. Clearly, [LDL] has the highest sensitivity to d. The sensitivity to other
parameters is summarised in Table 3: dL virtually only affects [LDL], as in-
dicated by (6)–(9); variations of e = b/c displace the bifurcation point (16),
but [IC] is fairly insensitive; variations in kI and dI have a large effect on
[LDL], but only dI affects [IDL]; the sensitivity of [IC] to χI is moderate as
compared to the sensitivity of [LDL] or [IDL] to kI and dI .
We have also performed a Monte Carlo sensitivity analysis with respect to
variations of all parameters at once by sampling and averaging over the uni-
form hypercube of non-control parameters in Table 3. The results show that
the median sensitivity of [LDL] to global parametric variations is an order of
magnitude larger than that of [IC] over the low cholesterol branch. The con-
clusion of the sensitivity analysis is that while the plasma cholesterol [LDL]
is sensitive to most parameters, the intracellular cholesterol [IC] is robust to
parameter perturbations. In essence, this is a system where [IC] is tightly con-
trolled whereas [LDL] (the variable measured medically) is poorly controlled
and can undergo wide variations.
Based on experimental observations (Goldstein and Brown, 1977), we have
modelled the regulation of the nuclear synthesis of LDL receptors as a simple
reciprocal feedback. However, the qualitative features of the system are robust
to our choice of functional form. The regulation term in Eq. (4) is a particular
case of the standard inhibiting feedback (Murray, 1990): c(1−φLR)/(q+[IC]
n),
with n = 1 and q ≪ [IC]. Note, however, that the presence of q and n does not
change the bounds (6)–(9). Therefore, the low and high cholesterol asymptotic
regimes and the asymptotic response of the system to time-varying inputs
(Section 4.2) remain unchanged. We have also checked numerically that the
system still undergoes transitions between low and high cholesterol states;
q and n have the effect of displacing the bifurcation points and modifying
the extent of the coexistence region. In general, for large q the effect of the
feedback is reduced, thus making the transition to the high cholesterol branch
easier; for n > 1 the feedback is more efficient, thus enlarging the region of
existence of the lower cholesterol branch.
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4 Physiological Implications of the Model
4.1 Parametric Effects of Medical and Genetic Conditions
4.1.1 Tangier Disease and Reverse Cholesterol Transport
Tangier disease is a deadly disease in which vanishing reverse cholesterol
transport leads to accumulation of cholesterol in all cells (Young and Fielding,
1999). In our model, the parameter dIC depends directly on reverse cholesterol
transport. Note that only the bounds on [IC]eq are inversely proportional to
dIC . This means that low values of dIC lead to diverging levels of intracellular
cholesterol, while the plasma cholesterol levels saturate (Fig. 3).
4.1.2 Lipase Enzyme Activity
In a review article, Stein and Stein (2003) report that reduced enzyme activity
can lead to reduced plasma cholesterol concentrations in mice and rabbits.
Similar results might hold for humans. A conclusion of our sensitivity analysis
(Table 3) is that variations in kI produce sharp changes in [LDL] without
affecting the other variables significantly. Further numerics (not shown) show
that decreasing kI decreases [LDL].
4.1.3 Familial Hypercholesterolemia
Familial hypercholesterolemia (FH) is a genetic disease caused by mutations
in the LDL receptor gene (Goldstein and Brown, 1977; Hobbs et al., 1990). In
the heterozygous case of FH, which affects about 1 in 500 people in generic
populations and even higher ratios in more inclusive populations, cells express
around half the normal number of functional receptors on their surface lead-
ing to a two-fold increase in [LDL]. The homozygous case is much more rare
(about 1 per million) but more severe. In this case, a negligible amount of
functional LDL receptors lead to a dramatic rise of LDL plasma levels. These
diseased individuals frequently dye of myocardial infarction or stroke in their
teens. Table 4 presents a classification of FH gene mutations with their phys-
iological implications (Hobbs et al., 1990). We also show how the mutations
can be represented in terms of the parameters of our model.
Most of the medical observations in Hobbs et al. (1990) refer to mutation
classes 3 and 4, both hetero- and homozygous. In terms of our model, het-
erozygous mutations 3 and 4 would halve dI and dL. This produces roughly a
two-fold (up to four-fold) increase in [LDL], as deduced from the lower bound
in (7) and Table 2. One of the homozygous mutations blocks the binding of
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Mutation Class Physiological effect Affected Parameter
1 Reduced synthesis of LR
c ↓
2 Reduced transport of LR
3 Reduced binding of IDL/LDL to LR
dI ↓ and/or dL ↓
4 Reduced number of LR in coated pits
5 Diminished recycling of LR b ↑
Table 4
Gene mutations that lead to familial hypercholesterolemia.Mutations lead-
ing to FH as classified by Hobbs et al. (1990) and how they affect the parameters
of the model.
both IDL and LDL to LR, hence dI = dL = 0. Again from (7), this would
increase [LDL] by a factor (1+dL/d)(1+dI/kI), which is roughly 10-fold (and
up to several hundred times-fold). These numerical factors correspond well to
those in the literature (Hobbs et al., 1990). Under another homozygous mu-
tation 3 and 4, LDL receptors bind to IDL but not to LDL, i.e., dL = 0. This
produces an increase of [LDL] in the lower branch by a factor of (1 + dL/d),
which is two-fold (up to nine-fold) but still an order of magnitude smaller than
that of the other homozygous case. Moreover, the characteristic time scale for
the catabolism of LDL (see Section 4.2) increases from (d+dL)
−1 (around two
days) to d−1 (over a week). Again, this coincides with experimental observa-
tions that the removal of LDL from the plasma is delayed and the increase in
plasma LDL is moderate (Hobbs et al., 1990).
Medical evidence for mutations 1-2 and 5 is scarcely reported. In our model,
they would translate into an increase of e = b/c which would have a small
effect on the plasma concentrations on the lower cholesterol branch. However,
as seen in Eqs. (15) and (16), an increase in e would lower the bifurcation
point, making it easier to jump to the high cholesterol branch in response to
an increase in uV or a decrease in dIC . Therefore, under these mutations the
parameter region where the lower cholesterol regime exists would be reduced.
Other observations in Hobbs et al. (1990) could also be interpreted in terms of
our model. For example, it was reported that despite treatment with statins
and lipid-lowering medications, the plasma cholesterol of some patients re-
mained between 600 and 1200mg/dl, five to ten times the normal levels. As
seen in Figs. 2 and 3 and discussed further in Section 4.2.1, the presence of
bistability means that once on the upper branch it is more difficult to return
to the low cholesterol state by reducing uV , e.g. through statin medication.
Another intriguing observation is the dramatic clinical variability among FH
patients with the same genetic mutation. A possible explanation is the ro-
bustness of [IC]eq to variations in the physiological parameters. Indeed, from
the lower bound in (9) we estimate that [IC] would only increase by 1.1 to
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1.5 times under homozygotic FH, while the corresponding increase in [LDL]
would range from one to almost three orders of magnitude. This would allow
the development of individuals who would have similar levels of intracellular
cholesterol while the LDL plasma levels could be very high in some cases, with
different clinical consequences.
4.2 Response to Time-dependent Inputs
The time scales of the system span from a few hours up to a week. These
time scales govern the way in which the system responds to external drives or
perturbations to the variables. To clarify their dynamical role, we use singular
perturbation methods to obtain slow and fast manifolds (Khalil, 2000) relevant
to the system. We have seen previously that the lower bound (φLR = 1) and
upper bound (φLR = 0) are approached asymptotically as uV → 0 and as
uV →∞, respectively. In these singular asymptotic limits, the system (1)–(5)
reduces to a linear system of the form:
dx
dt
= Ak x+ b, k = {l, u}, (17)
where x = [[V LDL] [IDL] [LDL] [IC]]T, b = [uV 0 0 0]
T,
Al =


−kV 0 0 0
kV −kI − dI 0 0
0 kI −dL − d 0
0 χIdI χL(dL + d) −dIC


, Au =


−kV 0 0 0
kV −kI 0 0
0 kI −d 0
0 0 χLd −dIC


,
and l, u denote lower and upper asymptotic regimes, respectively. The inverse
of the matrix eigenvalues are the characteristic times for each variable to return
to equilibrium:
(kI + dI)
−1 ≈ 0.5 < d−1IC ≈ 1 h < k
−1
V ≈ 10
< k−1I ≈ 40 < (d+ dL)
−1 ≈ 70 < d−1 ≈ 200, (18)
all of them given in hours. Note that the slowest time scale increases from
(d+ dL)
−1 (on the scale of a day) on the lower branch to d−1 (over one week)
on the upper branch.
4.2.1 Response to slow drifts in the control parameters
The response of the system to a slowly drifting input uV (t), which varies on
a time scale slower than d−1, will be quasi-static, tracking the equilibrium
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Fig. 4. Quasi-static nonlinear effects (a) Hysteresis curve obtained when uV is
increased by 0.01 g(lh)−1 every 1000 hours from uV = 1 g(lh)
−1 to uV = 2 g(lh)
−1,
and then decreased at the same rate to its initial value. (b) Bottleneck dynamics
caused by the ‘ghost’ saddle-node around the bifurcation. The jump to the upper
branch occurs a year after a small, but permanent, perturbation of uV has occurred.
points. This can reveal nonlinear behaviour, such as hysteresis and bottleneck
phenomena (Strogatz, 1994), which can have physiological ramifications.
If the system is in a parametric region where it can undergo bifurcations (as in
Figs. 2 and 3), it will exhibit standard hysteresis when uV is swept continuously
from the lower branch to the upper branch and backwards (Figure 4a). This
means that once in the upper branch it is more difficult to return to the low
cholesterol state by reducing uV (e.g., through statin medication).
Another effect of the existence of saddle-node bifurcations is the possibility
of bottleneck dynamics caused by saddle-node ghosts. This can translate into
long-lived transients when the system is parametrically close to the bifurcation
points. Figure 4b shows the time evolution of the system for two values of
uV , one below and one above (but very close) to the bifurcation. The former
remains in the low cholesterol branch and the latter jumps the high cholesterol
solution. However, although the actual transition is relatively sudden (on the
order of a week, d−1), it occurs after a prolonged period of more than a year
in which the system behaves as if in the (no longer existing) low cholesterol
state. This pseudo-steady (ghost) behaviour would make it difficult to detect a
very slow uV drift, which can suddenly lead to high plasma cholesterol values,
if clinical measurements are infrequent.
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4.2.2 Response to periodic inputs
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Fig. 5. Forced oscillations with a period of one day. Response of [IDL],
[LDL] and [IC] to a periodic forcing uV = UV (1 + sin(ω t)) with ω = 2pi/24h
−1
for values of UV = 1.25 (solid line), 1.75 (dashed line), 2.25 (dot-dashed line). All
other parameters as in Fig. 2. The variables of the system exhibit different dynamical
responses at this forcing frequency. The variability of [IC] is linked to that of [IDL]
on the lower branch and to that of [LDL] on the upper branch.
We study now the physiological implications of the response of the system to
forced input oscillations with periods of days up to months. It is reasonable
to assume that the production of VLDL (uV (t)) can have a strong periodic
content on the order of a day since VLDL is produced at increased levels
during the night; dietary intake is often highly cyclic; and the ingestion of
statins to lower uV generally follows a daily cycle. As expected, entrainment
phenomena can be observed in Figure 5, where we show the response of the
system to forced oscillations with period of one day and increasing amplitude
and mean. [LDL] is relatively insensitive to the oscillatory drive, while [IDL]
exhibits large oscillatory amplitudes both for small and large drives. However,
the salient feature is the different amplitude of the response of [IC] in both
regimes. Qualitatively, this can be understood from the fact that [IC] changes
from being tightly linked to [IDL] at low drives, when the amount of LDL
receptors is high, to being governed by [LDL] on the upper branch, where the
low φLR makes IDL endocytosis virtually impossible while LDL can still be
absorbed through the non-receptor mediated route.
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A quantitative understanding of the responses in Figure 5 emerges from a
more detailed analysis. If we consider a periodic input
uV (t) = UV (1 + P sin(ω t)) , (19)
it follows that the time response of the asymptotic system (17) is sinusoidal
of the form
xi = xi,av + xi,s sin(ω t) + xi,c cos(ω t), i = 1, . . . , 4, (20)
with average xi,av and amplitude xi,amp =
√
x2i,s + x
2
i,c. We have calculated
the sinusoidal responses for [IDL], [LDL] and [IC] on both branches. On the
lower branch we get:
[IDL]av,l =
UV
kI + dI
,
[IDL]amp,l
[IDL]av,l
=
P√(
1 +
(
ω
kV
)2) (
1 +
(
ω
kI+dI
)2) (21)
[LDL]av,l =
kI UV
(kI + dI) (d+ dL)
,
[LDL]amp,l
[LDL]av,l
=
[IDL]amp,l
[IDL]av,l
1√
1 +
(
ω
d+dL
)2 (22)
[IC]av,l =
(χIdI + χLkI)UV
(kI + dI) dIC
,
[IC]amp,l
[IC]av,l
=
[IDL]amp,l
[IDL]av,l
√√√√√√√
1 +
(
ω
d+dL
χIdI
χIdI+χLkI
)2
(
1 +
(
ω
d+dL
)2) (
1 +
(
ω
dIC
)2) , (23)
while on the upper branch we obtain:
[IDL]av,u =
UV
kI
,
[IDL]amp,u
[IDL]av,u
=
P√(
1 +
(
ω
kV
)2)(
1 +
(
ω
kI
)2) (24)
[LDL]av,u =
UV
d
,
[LDL]amp,u
[LDL]av,u
=
[IDL]amp,u
[IDL]av,u
1√
1 +
(
ω
d
)2 (25)
[IC]av,u =
χLUV
dIC
,
[IC]amp,u
[IC]av,u
=
[LDL]amp,u
[LDL]av,u
1√
1 +
(
ω
dIC
)2 . (26)
The sinusoidal solutions (20)–(26), which are valid asymptotically in the limits
uV → 0 (lower) and uV →∞ (upper), provide a good approximation when UV
is either small or large. Clearly, one does not expect a pure sinusoidal response
at intermediate values of UV , as can be observed in Figure 5.
The change in the variability of [IC] on both branches can now be traced
to Eqs. (21)–(26). For a forcing period of one day (ω = π/12 ≈ 0.26 h−1)
19
and using the time scales (18), the key terms are ω/(d + dL) and ω/d. Note
how on the lower branch (23), the ω/(d + dL) terms cancel, with the effect
that the relative variability [IC]amp,l/[IC]av,l is tied to that of [IDL]. Onn
the upper branch (26), ω/dIC ≪ 1, which implies that the relative variability
[IC]amp,u/[IC]av,u is linked to that of [LDL].
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Fig. 6. Forced oscillations with a period of 100 days. (a) Response of [LDL]
to a periodic forcing uV = (1 + 0.2 sin(ω t)) with ω = 2pi/2400h
−1 for values of
dIC = [0.1, 0.2, 0.35, 0.45, 0.5], from top to bottom. All other parameters as in Fig. 3.
As dIC increases, the system moves from the upper to the lower branch and the av-
erage level of [LDL] decreases. (b) Relative amplitude of the oscillations, calculated
as the ratio of range and mean of the oscillations from numerical simulations. The
circles correspond to the values of dIC in (a). Note that the relative amplitude is
similar in both asymptotic regimes. This can be understood from Eqs. (22) and (25),
whence we obtain the relative amplitude to be ≈ 0.38 (as dIC → 0) and ≈ 0.40 (as
dIC → ∞). The relative amplitude reaches a maximum close to the bifurcation,
where the system jumps between the upper and lower branches and is at its most
nonlinear. As an indication, the bifurcation for these parameters and uV = 1 occurs
at dIC ≈ 0.373, close to the observed peak.
These observations suggest that the correlation between intracellular and
plasma cholesterol concentrations could be used as a marker to detect the
high cholesterol state. This effect would be most pronounced in hepatic cells
but might still be observable in other cells and detectable through a skin
test. (This would depend on how much IDL can penetrate peripheral cells by
leaking through the capillary endothelium into the interstitial fluid.) A less
practical alternative would imply repeated time measurements of [IDL] to
check for large amplitude oscillations.
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We have also explored the response of the system to oscillations with lower
frequency, as would be induced by seasonal cycles. Figure 6 shows the response
of [LDL] to oscillatory inputs with period of 100 days at different values of
dIC as shown in Fig. 3. Consistent with Eqs. (22) and (25), the average level
of [LDL] on the upper branch is high, of order ∼ d−1 ≈ 133, while on the
lower branch it is much smaller, of order ∼ kId
−1
I (d + dL)
−1 ≈ 0.7. However,
the relative amplitude of the oscillations of [LDL] in both asymptotic regimes
is of the same order. It is precisely at the bifurcation point, when the system
oscillates between the low and high cholesterol regimes, that the oscillations
are larger in relative terms (Figure 6). This could be used to characterise the
system if sufficiently frequent measurements are available.
5 Discussion
Understanding lipoprotein metabolism is important because high lipoprotein
concentration in the plasma is a major risk factor for atherosclerosis, the most
common cause of death in Western societies. We have introduced a dynamical
model of lipoprotein metabolism derived by combining physiological cascading
and cellular processes. The model goes beyond compartmental models in that
we have included both the nonlinear absorption of IDL and LDL by cells,
and a feedback mechanism by which the cell regulates the number of its LDL
receptors based on the concentration of intracellular cholesterol IC.
This low-dimensional, nonlinear model shows bistability and hysteresis be-
tween a low and a high cholesterol state. Our bifurcation analysis of the key
control parameters (uV and dIC) can be related to physiologically meaningful
processes: diet and statin medication in the case of uV ; reverse cholesterol
transport through HDL in the case of dIC. We have checked that the observed
behaviour is relatively robust with respect to all other parameters. An im-
portant outcome of our sensitivity analysis is that the most robust feature in
the low cholesterol state is the concentration of intracellular cholesterol [IC],
while the plasma concentrations [IDL] and [LDL] can vary widely. This indi-
cates that plasma cholesterol is not a tightly controlled variable in the system,
implying that very different values of plasma [LDL] can be compatible with vi-
able cellular function. It is conceivable, however, that the high levels of [LDL],
innocuous at the cellular level, could lead to the initiation of disease-linked
processes at the physiological level.
We have also obtained estimates for the characteristic time scales governing
the dynamics of the model in the low and high cholesterol states. These time
scales account for the dynamical responses of the system to forced input os-
cillations with very different periods. The model shows dynamical behaviour
which could be used to diagnose the state of the system if repeated mea-
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surements of plasma and/or cellular cholesterol with the correct timing and
periodicity are performed, as indicated by Figs. 5 and 6. If measurements are
too sparse, the onset of permanent high cholesterol levels might go undetected,
with the possibility of a difficult return to lower levels due to hysteretic ef-
fects. Measurements taken periodically on the order of hours or months could
provide complementary clues to the state of the system. If we assume that
periodic inputs to the system are important, measuring the relative variabil-
ity of LDL and cellular cholesterol (possibly through skin tests) could lead to
markers for the detection of the intrinsic regime of the system.
Our dynamical model is directly derived from the underlying physiological
and cellular processes. However, some of our approximations are crude and
several directions for improvement could be pursued. The level of the plasma
cholesterol on the high cholesterol branch ([V LDL]eq + [IDL]eq + [LDL]eq)
is unphysiologically high in the current model. This suggests the presence of
other physiological mechanisms of elimination that have not been included in
the model. Another extension would include time delays (Dugard and Verriest,
1998) to account for mass transfer (e.g., the delayed intake of IDL and LDL via
LR-mediated endocytosis) and control mechanisms (e.g., the delayed genetic
regulatory loop in the synthesis of LR). Furthermore, the model could be
extended to include explicitly the regulatory and synthetic pathways involving
the intracellular LDL receptors. It would also be important to distinguish
between hepatic and non-hepatic cells, as hepatic cells play a more central
role in lipoprotein metabolism. In particular, the rate of lipoprotein uptake
in liver cells is different; increased uptake of LDL in liver cells lowers the
production rate of VLDL (i.e., uV ) through an additional regulating feedback;
and statins reduce the inhibiting effect of [IC] on the synthesis of LR in liver
cells only.
Especially important would be to extend our description of reverse cholesterol
transport to include [HDL] explicitly as a variable. Indeed, 20% of the total
plasma cholesterol in healthy individuals (40mg/dl) is carried by HDL. Our
preliminary work in this direction indicates that the number of nonnegative
equilibria remains unchanged in the enlarged system that includes [HDL], and
the qualitative features of the system should hold. Because the relationship
between plasma [LDL] and [HDL] is of major importance in clinical trials,
this would be a crucial element to enhance the applicability of the model.
Further modelling of lipoprotein metabolism could bring light to several open
questions. To name but a few, it is still unknown why the plasma cholesterol
concentrations in adult humans are so unnecessarily high (Goldstein and Brown,
1977); what the exact effects of statins in the metabolic system are (Davidson and Jacobson,
2001); and which of the processes could be best targeted to reduce plasma LDL
concentrations.
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Appendices
A Derivation of the feedback term
The feedback term in Eq. (4) follows from a more detailed (but still simpli-
fied) derivation that includes the three compartments of intra-cellular LDL
receptors (complexed, recycled, nucleus-synthesised) as shown in Figure A.1.
The kinetic rate equations are:
d[LRcomp]
dt
= βα (dI [IDL] + dL[LDL])φLR − ǫ[LRcomp] (A.1)
d[LRrec]
dt
= ǫ(1− γ)[LRcomp]− δ[LRrec] (1− φLR) (A.2)
d[LRnuc]
dt
=
c1
[IC]
− k[LRnuc]− δ[LRnuc] (1− φLR) (A.3)
dφLR
dt
= −α (dI [IDL] + dL[LDL])φLR +
δ
β
([LRrec] + [LRnuc]) (1− φLR) .
(A.4)
If we assume steady-state conditions: d[LRcomp]
dt
= d[LRrec]
dt
= d[LRnuc]
dt
= 0, and
that k ≫ δ, then Eq. (4) follows with b = αγ and c = δc1/βk.
LR Synthesis 
ΦLR
Ø
Ø
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1 /β
(1-γ)ε
β
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δ(1-ΦLR)
1 /β
α(dI[IDL]+dL[LDL])
Fig. A.1. Schematic description of the feedback term. An expanded view of
the portion of Figure 1 that is related to the processes involved in the synthesis
and recycling of LDL receptors inside the cell. If we assume steady state for the
intracellular LR compartments, and that the turnover of nucleus-synthesised LR (k)
is large compared to the probability of its insertion into the membrane (δ), these
processes lead to Equation (4). The factor β performs the appropriate dimensional
conversions to account for the fact that φLR is a non-dimensional surface occupancy
fraction. Note also that γ is the fraction of non-recycled LDL receptors. All the other
constants are rate constants with the appropriate units.
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